/
/
/

Gufic Biosciences Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---15%
----8%
28%17%16%18%
13%13%13%10%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
GUFICBIO
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr
424₹4381 Cr59.652.2310.4₹64 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024
———
₹10 Cr₹10 Cr₹10 Cr
₹0₹10 L₹0
₹655 Cr₹591 Cr₹523 Cr
₹655 Cr₹591 Cr₹523 Cr
₹665 Cr₹601 Cr₹533 Cr
₹4 L₹0₹0
₹105 Cr₹131 Cr₹154 Cr
₹17 Cr₹8 Cr₹2 Cr
₹20 Cr₹25 Cr₹17 Cr
₹18 Cr₹17 Cr₹15 Cr
₹160 Cr₹181 Cr₹188 Cr
———
₹199 Cr₹159 Cr₹166 Cr
₹58 Cr₹70 Cr₹56 Cr
₹254 Cr₹154 Cr₹142 Cr
₹6 Cr₹4 Cr₹7 Cr
₹518 Cr₹388 Cr₹372 Cr
₹1342 Cr₹1169 Cr₹1093 Cr
₹12 Cr₹6 Cr₹7 Cr
₹385 Cr₹310 Cr₹317 Cr
———
₹630 Cr₹614 Cr₹246 Cr
₹139 Cr₹108 Cr₹87 Cr
₹491 Cr₹506 Cr₹159 Cr
₹22 Cr₹22 Cr₹307 Cr
₹2 Cr₹2 Cr₹2 Cr
₹2 Cr₹2 Cr₹2 Cr
₹24 Cr₹13 Cr₹23 Cr
₹2 Cr₹2 Cr₹1 Cr
₹540 Cr₹545 Cr₹492 Cr
———
₹324 Cr₹217 Cr₹200 Cr
₹297 Cr₹315 Cr₹330 Cr
₹76 Cr₹29 Cr₹13 Cr
₹2 Cr₹2 Cr₹4 Cr
₹102 Cr₹63 Cr₹53 Cr
₹802 Cr₹625 Cr₹600 Cr
₹284 Cr₹237 Cr₹228 Cr
₹1342 Cr₹1169 Cr₹1093 Cr
₹66₹60₹53
₹66₹60₹53

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024
₹87 Cr₹94 Cr₹116 Cr
₹65 Cr₹44 Cr₹34 Cr
-₹95 Cr₹7 Cr-₹130 Cr
₹57 Cr₹145 Cr₹20 Cr
₹45 Cr₹123 Cr-₹7 Cr
-₹31 Cr-₹71 Cr-₹102 Cr
₹32 Cr-₹37 Cr₹82 Cr
₹46 Cr₹15 Cr-₹27 Cr
₹16 Cr₹1 Cr₹29 Cr
₹62 Cr₹16 Cr₹1 Cr

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)437.45
Volume (₹)70,169.00
High (₹)441.95
Upper Circuit524.90
Low (₹)417.60
Lower Circuit350.00
Prev Close437.45
52W High (₹)467.80
Price424.00
52W Low (₹)268.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)4381.34 Cr
Div. Yield (%)0.02
PE Ratio59.65
Debt to Equity0.58
Price to Book4.14
Book Value66.31
EPS (TTM)7.33
Face Value1.00
ROE (%)10.14

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
GUFICBIONSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
424-12 (-2.75%)
417.60
449
4,381Cr

Gufic Biosciences Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹47.06Cr; with other income of ₹45.8Lakh, profit before interest and tax came to ₹39.36Cr. Interest expense was ₹9.32Cr; PBT before exceptional items stood at ₹30.04Cr. Cost mix (full year): raw materials ₹418.02Cr; employee cost ₹151.68Cr; depreciation ₹7.71Cr; other expenses ₹214.21Cr. Basis: consolidated annual results.

Gufic Biosciences Ltd Quaterly Results Key Takeaways

Gufic Biosciences Ltd reported ₹260.82Cr total income from operations in Jun 2026, softer than ₹251.82Cr in Mar 2026 but higher than ₹223.72Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹47.06Cr; with other income of ₹45.8Lakh, profit before interest and tax came to ₹39.36Cr. Interest expense was ₹9.32Cr, taking profit before tax to ₹30.04Cr. After tax of ₹7.73Cr, profit after tax stood at ₹22.31Cr (vs ₹21.9Cr in Mar 2026 and ₹13.07Cr in Jun 2025).